Cullinan Therapeutics Inc (NASDAQ: CGEM) on Monday, plunged -4.02% from the previous trading day, before settling in for the closing price of $20.16. Within the past 52 weeks, CGEM’s price has moved between $7.64 and $30.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -20.00%. The company achieved an average annual earnings per share of 17.90%. With a float of $40.68 million, this company’s outstanding shares have now reached $42.90 million.
The extent of productivity of a business whose workforce counts for 85 workers is very important to gauge.
Cullinan Therapeutics Inc (CGEM) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cullinan Therapeutics Inc is 29.42%, while institutional ownership is 45.48%. The most recent insider transaction that took place on Jul 05 ’24, was worth 130,640. In this transaction Chief Scientific Officer of this company sold 8,000 shares at a rate of $16.33, taking the stock ownership to the 123,942 shares. Before that another transaction happened on May 07 ’24, when Company’s Chief Scientific Officer sold 5,606 for $30.06, making the entire transaction worth $168,516. This insider now owns 129,582 shares in total.
Cullinan Therapeutics Inc (CGEM) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 17.90% per share during the next fiscal year.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Cullinan Therapeutics Inc (CGEM) is currently performing well based on its current performance indicators. A quick ratio of 20.33 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.14, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -3.06 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
The latest stats from [Cullinan Therapeutics Inc, CGEM] show that its last 5-days average volume of 0.75 million was superior to 0.71 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 70.26%. Additionally, its Average True Range was 1.33.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 28.73%, which indicates a significant decrease from 68.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.57% in the past 14 days, which was lower than the 83.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.81, while its 200-day Moving Average is $15.70. Now, the first resistance to watch is $20.20. This is followed by the second major resistance level at $21.04. The third major resistance level sits at $21.72. If the price goes on to break the first support level at $18.67, it is likely to go to the next support level at $17.99. The third support level lies at $17.15 if the price breaches the second support level.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
Market capitalization of the company is 1.12 billion based on 57,634K outstanding shares. Right now, sales total 0 K and income totals -153,160 K. The company made 0 K in profit during its latest quarter, and -37,150 K in sales during its previous quarter.
